CAR T 細胞療法市場：按目標抗原、治療應用、治療方法、最終用戶和地區分類。

CAR T-cell Therapy Market, By Targeted Antigen, By Therapeutic Application, By Therapy Type, By End User, By Geography

出版日期: 2026年04月24日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計 CAR T 細胞療法市場在 2026 年的價值為 48.3 億美元，到 2033 年將達到 184.6 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 21.1%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	48.3億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	21.10%	2033年市場規模預測：	184.6億美元

嵌合體抗原受體（CAR）T細胞療法是一種利用免疫T細胞摧毀癌細胞的免疫療法。由於CAR T細胞療法涉及T細胞的基因改造，因此也稱為基於細胞的基因療法。在CAR T細胞療法中，首先透過白血球分離術從人體內採集T細胞。然後，透過引入嵌合體嵌合體受體（CAR）基因對這些採集的T細胞進行改造，改造後的細胞稱為CAR-T細胞。改造後，這些細胞被培養並輸注到體內。目前已開發出多種CAR T細胞療法來對抗特定類型的癌症。 CAR-T細胞根據每位患者的個別情況進行客製化，然後注射到血液中。 CAR T細胞療法正被用作一種治療癌症的新型基因治療方法。目前，正在進行多項臨床和臨床前試驗，以檢驗不同CAR T細胞療法對特定癌症的安全性和有效性。此外，一些政府機構正在進行提高公眾對癌症意識的舉措，例如美國疾病管制與預防中心（CDC）所進行的宣傳活動。

市場動態

預計在預測期內，市場主要參與者產品核可等有機成長策略的日益普及將推動市場成長。例如，2022年5月，全球領先的醫療保健公司之一諾華公司（Novartis AG）的CAR-T細胞療法Kymriah（tisagenlecleucel）獲得美國食品藥物管理局（FDA）核准，用於治療復發或難治性濾泡性淋巴瘤成人患者。此核准是基於一項II期臨床試驗的結果，該試驗顯示68%的患者有效率達到緩解。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本報告根據以下參數對全球 CAR T 細胞療法市場的主要參與者進行了分析：公司亮點、產品系列、主要特點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球 CAR T 細胞療法市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球 CAR T 細胞療法市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第9章競爭情勢

Bristol-Myers Squibb Company
Johnson &Johnson Services, Inc.
Novartis AG
Gilead Sciences, Inc.
Legend Biotech
bluebird bio, Inc.
CARsgen Therapeutics Co., Ltd.
Mustang Bio
Fate Therapeutics
Sorrento Therapeutics, Inc.

第10章分析師建議

機會
分析師意見
Coherent Opportunity Map

第11章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI102

CAR T-cell Therapy Market is estimated to be valued at USD 4.83 Bn in 2026 and is expected to reach USD 18.46 Bn by 2033, growing at a compound annual growth rate (CAGR) of 21.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 4.83 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	21.10%	2033 Value Projection:	USD 18.46 Bn

Chimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy which uses immune T cells to destroy cancer. CAR T cell therapy is also called as cell based gene therapy, as it involves gene altering in T cells. For chimeric antigen receptor (CAR)-T cell therapy, T cells are extracted from human body using a procedure called leukapheresis. Then after extraction, T cells are altered by adding the gene for the specific chimeric antigen receptor (CAR) and hence they are called as CAR T cells. After the alteration, the cells are kept to grow and then are infused into human body. Different type of CAR T cell therapy are made to fight specific type of cancer. CAR- T cells are customized for different patients and then infused in blood. CAR T cells therapy is used as a novel gene therapy to fight cancer. Different clinical and preclinical studies are going on to study the safety and efficacy of various CAR-T cell therapies for specific cancer. Moreover, several governments are taking initiatives such as campaigns to spread the awareness of cancer for example educational campaign by Centers for Disease Control and Prevention (CDC).

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product approval is expected to drive market growth over the forecast period. For instance, in May 2022, Novartis AG., one of the global healthcare company, received the U.S. Food and Drug Administration approval for Kymriah (tisagenlecleucel) CAR-T cell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on phase II clinical trial, evaluated with 68% of positive response from the patients.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global CAR T cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global CAR T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global CAR T cell therapy market.

Market Segmentation

Global CAR T Cell Therapy Market, By Targeted Antigen
- CD19
- BCMA
- HER2
- GD2
- CD20
- CD22
- CD30
- CD33
- HER1
- Others (CLDN18, etc.)
Global CAR T Cell Therapy Market, By Therapeutic Application
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others (Gastric Cancer, etc.)
Global CAR T Cell Therapy Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- CARsgenTherapeutics Co., Ltd.
- Aurora Biopharma
- Legend Biotech
- Gilead Sciences, Inc.
- Pfizer Inc.
- bluebird bio, Inc.
- Sorrento Therapeutics, Inc.
- Mustang Bio
- Fate Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global CAR T-cell Therapy Market, By Targeted Antigen
- Global CAR T-cell Therapy Market, By Therapeutic Application
- Global CAR T-cell Therapy Market, By Therapy Type
- Global CAR T-cell Therapy Market, By End User
- Global CAR T-cell Therapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trends

4. Global CAR T-cell Therapy Market, By Targeted Antigen, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
CD19
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
BCMA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
HER2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
GD2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
CD20
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
CD22
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
CD30
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
CD33
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
HER1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global CAR T-cell Therapy Market, By Therapeutic Application, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hematological Malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Solid Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global CAR T-cell Therapy Market, By Therapy Type, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Autologous CAR T-cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Allogeneic CAR T-cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global CAR T-cell Therapy Market, By End User, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

8. Global CAR T-cell Therapy Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Targeted Antigen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Legend Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
bluebird bio, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CARsgen Therapeutics Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Mustang Bio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Fate Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sorrento Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies